TNYA
Tenaya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.67
−0.27%0
Insider buys (3m)
7
Insider sells (3m)
-$19.9K
Net value (3m)
-2.9%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 11, 2026 | Ali Faraz · director, officer: Chief Executive Officer | A-Award | 122,000 | $0.00 |
| Sep 11, 2026 | Ali Faraz · director, officer: Chief Executive Officer | A-Award | 732,500 | $0.65 |
| Sep 11, 2026 | Tingley Whittemore · officer: Chief Medical Officer | A-Award | 49,000 | $0.00 |
| Sep 11, 2026 | Tingley Whittemore · officer: Chief Medical Officer | A-Award | 293,000 | $0.65 |
| Aug 17, 2026 | Tingley Whittemore · officer: Chief Medical Officer | Sale | 2,279 | $0.71 |
| Aug 17, 2026 | Ali Faraz · director, officer: Chief Executive Officer | Sale | 5,837 | $0.71 |
| Aug 17, 2026 | Ali Faraz · director, officer: Chief Executive Officer | Sale | 3,969 | $0.71 |
| Aug 17, 2026 | Ali Faraz · director, officer: Chief Executive Officer | Sale | 5,020 | $0.71 |
| Aug 17, 2026 | Ali Faraz · director, officer: Chief Executive Officer | Sale | 7,406 | $0.71 |
| Aug 17, 2026 | Tingley Whittemore · officer: Chief Medical Officer | Sale | 1,637 | $0.71 |
| Aug 17, 2026 | Tingley Whittemore · officer: Chief Medical Officer | Sale | 1,871 | $0.71 |
| Jul 14, 2026 | Hyllengren Eric J · officer: Chief Financial Officer | A-Award | 1,650,000 | $0.84 |
| May 29, 2026 | Burroughs Amy L. · director | A-Award | 120,000 | $0.80 |
| May 29, 2026 | Williams R Sanders · director | A-Award | 120,000 | $0.80 |
| May 29, 2026 | Walsh Jeffrey T. · director | A-Award | 120,000 | $0.80 |
| May 29, 2026 | Stehman-Breen Catherine · director | A-Award | 120,000 | $0.80 |
| May 29, 2026 | Srivastava Deepak · director | A-Award | 120,000 | $0.80 |
| May 29, 2026 | Lee June · director | A-Award | 120,000 | $0.80 |
| May 29, 2026 | Parschauer Karah Herdman · director | A-Award | 120,000 | $0.80 |
| May 19, 2026 | Ali Faraz · director, officer: Chief Executive Officer | Sale | 3,390 | $0.79 |
| May 19, 2026 | Tingley Whittemore · officer: Chief Medical Officer | Sale | 3,121 | $0.79 |
| May 19, 2026 | Higa Tomohiro · officer: SVP, Finance | Sale | 1,485 | $0.79 |
| Feb 26, 2026 | COLUMN GROUP III GP, LP · 10 percent owner | Sale | 349,212 | $0.62 |
| Feb 26, 2026 | COLUMN GROUP III GP, LP · 10 percent owner | Sale | 309,228 | $0.62 |
| Feb 26, 2026 | COLUMN GROUP III GP, LP · 10 percent owner | Sale | 1,862,545 | $0.56 |
| Feb 24, 2026 | COLUMN GROUP III GP, LP · 10 percent owner | Sale | 277,769 | $0.61 |
| Feb 24, 2026 | COLUMN GROUP III GP, LP · 10 percent owner | Sale | 162,291 | $0.60 |
| Feb 24, 2026 | COLUMN GROUP III GP, LP · 10 percent owner | Sale | 143,709 | $0.60 |
| Feb 24, 2026 | COLUMN GROUP III GP, LP · 10 percent owner | Sale | 245,965 | $0.61 |
| Feb 17, 2026 | Tingley Whittemore · officer: Chief Medical Officer | Sale | 1,876 | $0.64 |
Institutional positioning
13F filings over the trailing two quarters
New 44Increased 61Reduced 40Sold out 19
| Filer | Action | Shares | Filed |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 8,482,288 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Reduced | 7,101,263 | Aug 13, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 6,429,648 | Aug 14, 2026 |
| MILLENNIUM MANAGEMENT LLC | Increased | 5,456,666 | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 4,788,574 | Sep 2, 2026 |
| CITADEL ADVISORS LLC | Increased | 4,376,000 | May 15, 2026 |
| EMPERY ASSET MANAGEMENT, LP | Reduced | 4,286,933 | May 8, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 4,281,100 | Aug 13, 2026 |
| BlackRock, Inc. | Increased | 4,008,719 | Aug 7, 2026 |
| Empery Asset Management, LP | Reduced | 3,863,115 | Aug 11, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 3,713,761 | May 14, 2026 |
| BLACKROCK, INC. | Reduced | 3,703,955 | May 13, 2026 |
| MARSHALL WACE, LLP | Increased | 3,503,178 | Aug 13, 2026 |
| MARSHALL WACE, LLP | Increased | 2,705,390 | May 15, 2026 |
| GSA CAPITAL PARTNERS LLP | Increased | 2,669,033 | Aug 6, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 11, 2026